secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-11-10T21:36:37+00:00
Accession:  0001628280-26-072793
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Senti Biosciences signs $4.55M equity commitment with Celadon affiliate CPIF II-9, drawn quarterly through 2027
--------------------------------------------------------------------------------

- CPIF II-9 Limited, an entity affiliated with Celadon Partners SPV 24 Limited, commits to buy up to $4.55M of Senti common stock at the Nasdaq Rule 5635(d) "Minimum Price."
- Drawdowns at company option: $1.8M by Dec 31, 2026; $1.35M by Mar 31, 2027; $0.5M by June 30, 2027; $0.5M by Sept 30, 2027; $0.4M by Dec 31, 2027.
- Funding conditioned on Nasdaq Capital Market listing, continued employment of Timothy Lu as CEO and Jay Cross as CFO, any required stockholder approval, and a registration rights agreement.
- Shares to be issued unregistered under Section 4(a)(2)/Rule 506 to one accredited investor; company may waive any settlement if it obtains alternative financing.
- Investor must maintain uncalled capital or cash of at least the commitment amount; Senti may seek specific performance to compel funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026072793/0001628280-26-072793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026072793/snti-20261109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-072793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer